e-drug
[Top] [All Lists]

[e-drug] Viracept (nelfinavir) recall by Roche

E-DRUG: Viracept (nelfinavir) recall by Roche
--------------------------------------------

8 June 2007

WHO STATEMENT ON ROCHE'S VIRACEPT® RECALL

ROCHE have informed WHO today (08 June 2007) of the global recall their 
nelfinavir products (Viracept®) in accordance with European Medicines Agency 
(EMEA) and Swissmedic requirements (except USA, Canada and Japan).

The reason for the recall is identification of an unexpected contaminant in 
some batches of Viracept®. The contaminant is a known genotoxic substance. For 
further information,

please see the EMEA statement at:
http://www.emea.europa.eu/pdfs/general/direct/pr/25128307en.pdf .

Current stocks of Viracept® should be quarantined.

Adults or children currently taking Viracept® should not interrupt their 
therapy, that is they should not stop any of the antiretroviral (ARV) 
medications. However, they should see their antiretroviral therapy provider as 
soon as possible to change from Viracept® to a
suitable alternative.

Nelfinavir belongs to the Protease Inhibitor (PI) class of antiretroviral 
medicines. The PI class should be reserved for second-line therapy wherever 
possible, particularly in settings of limited ARV formularies. In choosing the 
PI for second-line therapy for adults and children a PI boosted by ritonavir 
(/r) is recommended for antiviral potency.

Adequate within-class substitutions for Viracept® are any of the following 
protease inhibitors - Lopinavir/ritonavir (LPV/r), Indinavir/ritonavir (IDV/r), 
Saquinavir/ritonavir (SQV/r), Atazanavir/ritonavir (ATV/r), and 
Fosamprenavir/ritonavir (FPV/r). LPV/r is the preferred boosted PI, as it has 
the advantage of being available as a fixed dose combination and has recently 
been approved in a new heat stable formulation, which
eliminates the need for refrigeration. In children, SQV is only licensed for 
use in children over 25kg and ATV and FPV are not yet approved for use.

Nelfinavir may exceptionally be being used as part of initial therapy for 
pregnant women. If it is the case and no other PI is available, then 
substitution of Viracept® by another active ARV from another class of drugs 
will need to be considered. Non-nucleoside reverse transcriptase inhibitors 
drugs need to be used with caution in pregnant women.
Nevirapine may be associated with toxicity in women with CD4 counts above
250 cells/mm3. Efavirenz should be avoided in the 1st trimester of pregnancy 
because of potential for birth defects and in children less than 3 years of 
age. Abacavir as part of a triple nucleoside regimen may also be considered.

In summary for patients needing to substitute Viracept®, options include:
. a boosted protease inhibitor;
. Nevirapine - with close observation for toxicity if CD4 is above 250 
cells/mm3 :
. Efavirenz - unless in the first trimester of pregnancy;
. triple nucleoside therapy.

For further details of current treatment recommendations, please refer to 
the following
web link: http://www.who.int/entity/hiv/pub/guidelines/en.


<Prev in Thread] Current Thread [Next in Thread>
  • [e-drug] Viracept (nelfinavir) recall by Roche, Wilbert Bannenberg <=